Cura Products Ltd

curaproducts.net

Cura Products are '​'Dedicated to Infection Control'​'​ and has been formed to provide a unique infection control solution to the care industry including Care Home, Hospices and Hospitals. We have seen the devastating effects of Infections on society and the lives of the victims and so, we have taken action to compile and ever expanding range of products designed to fight infection in the most effective way possible.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

CASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA

CASI Pharmaceuticals, Inc. | January 19, 2022

news image

CASI Pharmaceuticals, Inc. a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced today, that the U.S. Food and Drug Administration as granted Orphan Drug Designation for CNCT19, an investigational CD-19 directed CAR-T therapy, for the treatment of patients with Acute Lymphoblastic Leukemia. CNCT19 is currently being developed independently by Juventas to meet the urgent clinical needs of pati...

Read More

VIEWS AND ANALYSIS, PHARMACY MARKET

ALTRO PHARMACEUTICALS TEAMS UP WITH LSPEDIA TO PROVIDE CUTTING-EDGE TECHNOLOGY FOR FDA DSCSA COMPLIANCE

PRNewswire | July 31, 2023

news image

LSPedia, a leading SaaS provider specializing in product traceability solutions for the pharmaceutical industry, has partnered with Altro Pharmaceuticals, enabling Altro customers to easily comply with the Drug Supply Chain Security Act (DSCSA) ahead of the FDA's final deadline on November 27, 2023. Altro provides expertise and services to pharmaceutical manufacturers and wholesale distributors, helping them expand their businesses, streamline supply chain operations, increa...

Read More

TRUMP FULFILLED A LONGSTANDING CAMPAIGN PROMISE TO LOWER DRUG PRICES

East Idaho News | July 20, 2020

news image

President Donald Trump fulfilled to a longstanding campaign promise Friday — to lower drug prices. He signed four executive orders, including ones on importing medications from Canada and basing the cost of drugs in the US on their prices in other countries — both of which progressive Democrats, including Vermont Sen. Bernie Sanders, have pushed. The efforts, which largely reaffirm the policies of the administration, are unlikely to have an effect before...

Read More

CITIUS PHARMACEUTICALS ACHIEVES CHEMICAL MANUFACTURING AND CONTROL MILESTONES FOR MINO-LOK

Citius Pharmaceuticals | September 23, 2020

news image

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has achieved a number of significant milestones over the past several weeks for Mino-Lok®. Mino-Lok is an antibiotic lock solution being developed as an adjunctive therapy for patients with central line-associated bloodstream infections (CLABSIs) or catheter-related bloods...

Read More
news image

Pharmacy Market

CASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA

CASI Pharmaceuticals, Inc. | January 19, 2022

CASI Pharmaceuticals, Inc. a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced today, that the U.S. Food and Drug Administration as granted Orphan Drug Designation for CNCT19, an investigational CD-19 directed CAR-T therapy, for the treatment of patients with Acute Lymphoblastic Leukemia. CNCT19 is currently being developed independently by Juventas to meet the urgent clinical needs of pati...

Read More
news image

VIEWS AND ANALYSIS, PHARMACY MARKET

ALTRO PHARMACEUTICALS TEAMS UP WITH LSPEDIA TO PROVIDE CUTTING-EDGE TECHNOLOGY FOR FDA DSCSA COMPLIANCE

PRNewswire | July 31, 2023

LSPedia, a leading SaaS provider specializing in product traceability solutions for the pharmaceutical industry, has partnered with Altro Pharmaceuticals, enabling Altro customers to easily comply with the Drug Supply Chain Security Act (DSCSA) ahead of the FDA's final deadline on November 27, 2023. Altro provides expertise and services to pharmaceutical manufacturers and wholesale distributors, helping them expand their businesses, streamline supply chain operations, increa...

Read More
news image

TRUMP FULFILLED A LONGSTANDING CAMPAIGN PROMISE TO LOWER DRUG PRICES

East Idaho News | July 20, 2020

President Donald Trump fulfilled to a longstanding campaign promise Friday — to lower drug prices. He signed four executive orders, including ones on importing medications from Canada and basing the cost of drugs in the US on their prices in other countries — both of which progressive Democrats, including Vermont Sen. Bernie Sanders, have pushed. The efforts, which largely reaffirm the policies of the administration, are unlikely to have an effect before...

Read More
news image

CITIUS PHARMACEUTICALS ACHIEVES CHEMICAL MANUFACTURING AND CONTROL MILESTONES FOR MINO-LOK

Citius Pharmaceuticals | September 23, 2020

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has achieved a number of significant milestones over the past several weeks for Mino-Lok®. Mino-Lok is an antibiotic lock solution being developed as an adjunctive therapy for patients with central line-associated bloodstream infections (CLABSIs) or catheter-related bloods...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us